Literature DB >> 7822337

Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor.

C Smerz-Bertling1, A Duschl.   

Abstract

We have investigated tyrosine phosphorylation of cellular proteins induced by interleukin (IL) 4 and compared it with the effects of three related cytokines, IL-2, IL-7, and IL-13. We show here that both IL-4 and IL-13 stimulate tyrosine phosphorylation of the 140-kDa IL-4 receptor subunit, which suggests that this receptor protein is used by both cytokines. Receptor phosphorylation induced by IL-13 was both weaker and slower than with IL-4. Stimulation of cells with IL-2 and IL-7 induced identical phosphorylation patterns to each other but not phosphorylation of the 140-kDa IL-4 receptor subunit. The only signal appearing upon stimulation with any of the four cytokines was the weak phosphorylation of an unidentified protein of 160 kDa. SH2 domains of p56lck and p59fyn precipitated the same proteins as anti-phosphotyrosine antibodies after IL-4 stimulation, which suggests that a src-type kinase may be involved in signal transduction through the IL-4 receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822337     DOI: 10.1074/jbc.270.2.966

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain.

Authors:  R L Palmer-Crocker; C C Hughes; J S Pober
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 2.  IL-4: an important cytokine in determining the fate of T cells.

Authors:  J L Silva-Filho; C Caruso-Neves; A A S Pinheiro
Journal:  Biophys Rev       Date:  2014-01-09

3.  Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation.

Authors:  M Goebeler; B Schnarr; A Toksoy; M Kunz; E B Bröcker; A Duschl; R Gillitzer
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

4.  Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy.

Authors:  R Essner; Y Huynh; T Nguyen; M Rose; M Kojima; D S Hoon
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

5.  Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha.

Authors:  M G Malabarba; H Rui; H H Deutsch; J Chung; F S Kalthoff; W L Farrar; R A Kirken
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

Review 6.  Immunity to gastrointestinal nematode infections.

Authors:  D Sorobetea; M Svensson-Frej; R Grencis
Journal:  Mucosal Immunol       Date:  2018-01-03       Impact factor: 7.313

Review 7.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

8.  Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation.

Authors:  A D Keegan; J A Johnston; P J Tortolani; L J McReynolds; C Kinzer; J J O'Shea; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

10.  Growth inhibition signalled through the interleukin-4/interleukin-13 receptor complex is associated with tyrosine phosphorylation of insulin receptor substrate-1.

Authors:  B Schnyder; H Lahm; G Woerly; N Odartchenko; B Ryffel; B D Car
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.